ClinicalTrials.gg
TerminatedNCT03917381Updated Sep 9, 2026Results posted

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

A Phase 1/2 interventional study of Acasunlimab and Acasunlimab in combination with docetaxel (in a single expansion cohort) in Solid Tumors, sponsored by Genmab. Terminated at 57 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
429
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of patients with certain types of cancer. All subjects will receive active drug; no one will receive placebo.

This trial has 2 parts. The purpose of the first part is to find out if acasunlimab at various doses is safe and to find out the best doses of acasunlimab to use. The purpose of the second part is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected in the first part work against cancer when given alone and how well they work when given with pembrolizumab with or without chemotherapy.

Trial details include:

  • The average trial duration for an individual subject will be about 74 weeks.
  • The average treatment duration for an individual subject will be about 21 weeks.
  • The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.
Read the detailed description

The trial is an open-label, multi-center safety trial of acasunlimab (GEN1046). The trial consists of 2 consecutive parts: a first-in-human (FIH) dose escalation (phase 1) and an expansion (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

For Dose Escalation:

  • Have a or cytologically confirmed non-CNS solid tumor that is or unresectable and for whom there is no available standard therapy

For Expansion:

  • Have histologically or cytological confirmed diagnosis of , advanced and/or metastatic NSCLC, EC, UC, TNBC, SCCHN, or cervical cancer who are not anymore candidates for standard therapy For separate expansion cohorts: metastatic NSCLC without prior systemic treatment regimens for metastatic disease.

For Both Dose Escalation and Expansion

  • Have according to 1.1
  • Have (ECOG) 0-1
  • Have an acceptable hematological status
  • Have acceptable liver function
  • Have an acceptable coagulation status
  • Have acceptable renal function

Key Exclusion Criteria:

  • Have uncontrolled intercurrent illness, including but not limited to:

    • Ongoing or active infection requiring intravenous treatment with anti-infective therapy, or any ongoing systemic inflammatory condition requiring further diagnostic work-up or management during screening.
    • Symptomatic congestive heart failure (Grade III or IV as classified by the ), unstable angina pectoris or cardiac arrhythmia
    • Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management
    • Ongoing or recent evidence of disease
    • History of irAEs that led to prior checkpoint treatment discontinuation
    • Prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade
    • History of chronic liver disease or evidence of hepatic cirrhosis
    • History of non-infectious pneumonitis that has required or currently has pneumonitis
    • History of organ allograft (except for corneal transplant) or or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of acasunlimab
    • Serious, non-healing wound, skin ulcer (of any grade), or bone fracture
  • Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new (younger than 6 months) or progressive or stroke
  • Prior therapy:

    • Radiotherapy within 14 days prior to first dose of acasunlimab. Note: palliative radiotherapy will be allowed.
    • Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to acasunlimab administration. Accepted exceptions are bisphosphonates (e.g., pamidronate, zoledronic acid, etc.) and denosumab
  • Toxicities from previous anti-cancer therapies that have not adequately resolved

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
429 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Acasunlimab will be administered as monotherapy.

    Biological: Acasunlimab

  • Experimental
    Expansion

    Acasunlimab will be administered as monotherapy or in combination with either docetaxel, pembrolizumab, or pembrolizumab + standard chemotherapy in separate expansion cohorts.

    Biological: Acasunlimab · Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort) · Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort) · Biological: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)

Interventions

  • BiologicalAcasunlimab

    Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).

    Also known as: GEN1046, DuoBody®-PD-L1x4-1BB

  • BiologicalAcasunlimab in combination with docetaxel (in a single expansion cohort)

    Drug pages: Acasunlimab · Docetaxel

    Acasunlimab and docetaxel will be administered intravenously once every 21 days.

    Also known as: GEN1046, DuoBody®-PD-L1x4-1BB

  • BiologicalAcasunlimab in combination with pembrolizumab (in a separate expansion cohort)

    Drug pages: Acasunlimab · Pembrolizumab

    Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.

    Also known as: GEN1046, DuoBody®-PD-L1x4-1BB

  • BiologicalAcasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)

    Drug pages: Acasunlimab · Pembrolizumab

    Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.

    Also known as: GEN1046, DuoBody®-PD-L1x4-1BB

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)

    In this trial, a DLT was defined as any grade 5 toxicity, grade 4 neutropenia lasting more than 7 days, grade 3 and 4 febrile neutropenia, grade 4 thrombocytopenia for minimal duration of 7 days, grade 3\&4 hemorrhage associated with thrombocytopenia of ≥ grade 3 requiring platelet transfusion, grade 4 anemia, liver toxicity (transaminases and bilirubin elevations), grade 3 nausea that didn't respond to optimal antiemetic treatment within 7 days, grade ≥3 vomiting that didn't respond to optimal antiemetic treatment within 3 days, grade ≥3 diarrhea that didn't respond to optimal antidiarrheal treatment within 3 days, grade 3 immune-related adverse event (irAEs) that didn't improve to ≤ grade 1 within 7 days by appropriate care or with corticosteroids (with exceptions per protocol), any grade 4 irAE, any other ≥ grade 3 non-hematological adverse events (AE), which occurred during the first GEN1046 treatment cycle (with exceptions per protocol).

    Time frame: During first cycle (21 days)

  2. Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to approximately 5 years, 10 months

  3. Expansion Cohort 1: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 millimeters (mm). PR was defined as ≥30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs.

    Time frame: Up to approximately 5 years, 10 months

Secondary outcomes

  1. Combination Therapy Expansion Cohorts: Number of Participants With Treatment-emergent AEs

    An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to approximately 5 years, 10 months

  2. Dose Escalation: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of GEN1046

    Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.

    Time frame: Cycle 1 and Cycle 2 (cycles were 21 days)

  3. Dose Escalation: Maximum Observed Plasma Concentration (Cmax) of GEN1046

    Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.

    Time frame: Cycle 1 and Cycle 2 (cycles were 21 days)

  4. Number of Participants With Anti-drug Antibodies (ADAs) to GEN1046

    Venous blood samples were collected for measurement of serum concentrations of ADAs. A participant was considered as positive overall status if: (i) negative at baseline and at least one positive post-baseline result; or (ii) positive at baseline and at least one positive post-baseline result with a titer higher than baseline.

    Time frame: Up to approximately 5 years, 10 months

  5. Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: ORR

    ORR was defined as the percentage of participants with BOR of CR or PR based on RECIST. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs.

    Time frame: Up to approximately 5 years, 10 months

  6. Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with confirmed BOR of CR, PR, or stable disease (SD) according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Follow-up measurements must have met the SD criteria at least once and for a minimum time period of 6 weeks (±7 days) after first treatment.

    Time frame: Up to approximately 5 years, 10 months

  7. Duration of Response (DoR)

    DOR was defined as the time from first documentation of response (CR or PR) to the date of the first documented progression or death whichever occurred earlier based on RECIST v1.1. DOR only applied to participants whose confirmed best overall response was CR or PR (i.e., responders).

    Time frame: Up to approximately 5 years, 10 months

  8. Expansion Cohort 1: Progression Free Survival (PFS)

    PFS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to the first documented progression or death due to any cause, whichever occurred first based on RECIST version 1.1.

    Time frame: Up to approximately 5 years, 10 months

  9. Expansion Cohort 1: Overall Survival (OS)

    OS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to death due to any cause.

    Time frame: Up to approximately 5 years, 10 months

07

Results

Posted Aug 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
Started4596699944024382408322119401120271210168
Received at least 1 dose of trial treatment4596699944024382408322119401120271210168
Completed00000000000000000000000000
Not completed4596699944024382408322119401120271210168
Withdrew: Death357569982341629226723141628711215686
Withdrew: Lost to follow-up00200000031408021130011000
Withdrew: Withdrawal by subject00000001133404155150730010
Withdrew: Other than specified00000000100100001120000000
Withdrew: Ongoing in trial10010000004002020024226472

Outcome measures

PrimaryDose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)

In this trial, a DLT was defined as any grade 5 toxicity, grade 4 neutropenia lasting more than 7 days, grade 3 and 4 febrile neutropenia, grade 4 thrombocytopenia for minimal duration of 7 days, grade 3\&4 hemorrhage associated with thrombocytopenia of ≥ grade 3 requiring platelet transfusion, grade 4 anemia, liver toxicity (transaminases and bilirubin elevations), grade 3 nausea that didn't respond to optimal antiemetic treatment within 7 days, grade ≥3 vomiting that didn't respond to optimal antiemetic treatment within 3 days, grade ≥3 diarrhea that didn't respond to optimal antidiarrheal treatment within 3 days, grade 3 immune-related adverse event (irAEs) that didn't improve to ≤ grade 1 within 7 days by appropriate care or with corticosteroids (with exceptions per protocol), any grade 4 irAE, any other ≥ grade 3 non-hematological adverse events (AE), which occurred during the first GEN1046 treatment cycle (with exceptions per protocol).

Time frame:
During first cycle (21 days)
Reported as:
Count of participants · Participants
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)
ParticipantsDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mg
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)101021000
PrimaryDose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Count of participants · Participants
Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs)
ParticipantsDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W
Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs)4596698844024382398312119391127
PrimaryExpansion Cohort 1: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 millimeters (mm). PR was defined as ≥30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LDs.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Number · percentage of participants
Expansion Cohort 1: Objective Response Rate (ORR)
percentage of participantsExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W
Expansion Cohort 1: Objective Response Rate (ORR)12.5 (4.2 to 26.8)
SecondaryCombination Therapy Expansion Cohorts: Number of Participants With Treatment-emergent AEs

An AE was defined as any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Treatment-emergent AEs were any AEs that developed or worsened after the first dose of a medicinal product. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Count of participants · Participants
Combination Therapy Expansion Cohorts: Number of Participants With Treatment-emergent AEs
ParticipantsExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
Combination Therapy Expansion Cohorts: Number of Participants With Treatment-emergent AEs201210168
SecondaryDose Escalation: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of GEN1046

Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.

Time frame:
Cycle 1 and Cycle 2 (cycles were 21 days)
Reported as:
Geometric mean · µg*day/mL
Dose Escalation: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of GEN1046
µg*day/mLDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mg
Cycle 113.2 ± 51.946.4 ± 23.3104.7 ± 39.5221.3 ± 43.4250.3 ± 26.9369.4 ± 20.9936.3 ± 18.91922.6 ± 40.23189.8 ± 23.4
Cycle 213.4 ± 94.256.2 ± 28.1102.9 ± 33.5277.1 ± 36230.7 ± 38.5358.3 ± 43.91265.5 ± 23.972316.97 ± 37.44256.5 ± 33.1
SecondaryDose Escalation: Maximum Observed Plasma Concentration (Cmax) of GEN1046

Venous blood samples were collected for measurement of plasma concentrations of GEN1046. Data reported are average values for Cycle 1 and Cycle 2.

Time frame:
Cycle 1 and Cycle 2 (cycles were 21 days)
Reported as:
Geometric mean · ug/mL
Dose Escalation: Maximum Observed Plasma Concentration (Cmax) of GEN1046
ug/mLDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mg
Cycle 17.9 ± 13.816 ± 23.227.1 ± 28.148 ± 20.755 ± 29.163.5 ± 16.4125.7 ± 17.2249.2 ± 28.9429.2 ± 7.1
Cycle 27.2 ± 14.816.5 ± 33.126.1 ± 29.347.8 ± 29.547 ± 21.267.3 ± 23.8141.4 ± 17.1284.2 ± 30.4512 ± 13.4
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to GEN1046

Venous blood samples were collected for measurement of serum concentrations of ADAs. A participant was considered as positive overall status if: (i) negative at baseline and at least one positive post-baseline result; or (ii) positive at baseline and at least one positive post-baseline result with a titer higher than baseline.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to GEN1046
ParticipantsDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
Number of Participants With Anti-drug Antibodies (ADAs) to GEN1046226313763151120216117811254996742
SecondaryDose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: ORR

ORR was defined as the percentage of participants with BOR of CR or PR based on RECIST. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Number · percentage of participants
Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: ORR
percentage of participantsDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: ORR0 (0.0 to 60.2)0 (0.0 to 52.2)11.1 (0.3 to 48.2)16.7 (0.4 to 64.1)0 (0.0 to 45.9)0 (0.0 to 33.6)0 (0.0 to 33.6)0 (0.0 to 33.6)0 (0.0 to 60.2)8.3 (1.0 to 27.0)5.3 (0.6 to 17.7)0 (0.0 to 84.2)10.0 (2.8 to 23.7)0 (0.0 to 36.9)6.3 (0.8 to 20.8)4.8 (0.1 to 23.8)10.5 (1.3 to 33.1)7.5 (1.6 to 20.4)18.2 (2.3 to 51.8)15.0 (3.2 to 37.9)0 (0.0 to 12.8)25.0 (5.5 to 57.2)40.0 (12.2 to 73.8)37.5 (15.2 to 64.6)62.5 (24.5 to 91.5)
SecondaryDose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: Disease Control Rate (DCR)

DCR was defined as the percentage of participants with confirmed BOR of CR, PR, or stable disease (SD) according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have had a reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LDs. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of LDs while in trial. Follow-up measurements must have met the SD criteria at least once and for a minimum time period of 6 weeks (±7 days) after first treatment.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Number · percentage of participants
Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: Disease Control Rate (DCR)
percentage of participantsDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
Dose Escalation and Expansion Cohorts 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13: Disease Control Rate (DCR)25.0 (0.6 to 80.6)60.0 (14.7 to 94.7)88.9 (51.8 to 99.7)66.7 (22.3 to 95.7)50.0 (11.8 to 88.2)66.7 (29.9 to 92.5)77.8 (40.0 to 97.2)55.6 (21.2 to 86.3)75.0 (19.4 to 99.4)45.8 (25.6 to 67.2)50.0 (33.4 to 66.6)100 (15.8 to 100.0)40.0 (24.9 to 56.7)50.0 (15.7 to 84.3)37.5 (21.1 to 56.3)38.1 (18.1 to 61.6)73.7 (48.8 to 90.9)55.0 (38.5 to 70.7)54.5 (23.4 to 83.3)70.0 (45.7 to 88.1)37.0 (19.4 to 57.6)75.0 (42.8 to 94.5)80.0 (44.4 to 97.5)62.5 (35.4 to 84.8)100 (63.1 to 100.0)
SecondaryDuration of Response (DoR)

DOR was defined as the time from first documentation of response (CR or PR) to the date of the first documented progression or death whichever occurred earlier based on RECIST v1.1. DOR only applied to participants whose confirmed best overall response was CR or PR (i.e., responders).

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Median · months
Duration of Response (DoR)
monthsDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
Duration of Response (DoR)——28.942.79—————3.02 (2.79 to NA)NA (17.28 to NA)2.91 (2.30 to NA)—22.41 (4.60 to NA)—NA (2.79 to NA)4.0711.27 (NA to NA)12.68 (5.39 to NA)NA (2.83 to NA)6.97 (4.17 to NA)—10.28 (5.55 to NA)NA (2.96 to NA)13.54 (4.11 to NA)4.14 (1.71 to NA)
SecondaryExpansion Cohort 1: Progression Free Survival (PFS)

PFS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to the first documented progression or death due to any cause, whichever occurred first based on RECIST version 1.1.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Median · months
Expansion Cohort 1: Progression Free Survival (PFS)
monthsExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W
Expansion Cohort 1: Progression Free Survival (PFS)2.30 (1.38 to 2.69)
SecondaryExpansion Cohort 1: Overall Survival (OS)

OS was defined as the time from Day 1 in Cycle 1 (cycles were 21 days) to death due to any cause.

Time frame:
Up to approximately 5 years, 10 months
Reported as:
Median · months
Expansion Cohort 1: Overall Survival (OS)
monthsExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W
Expansion Cohort 1: Overall Survival (OS)6.11 (5.06 to 9.00)

Adverse events

Collected over Up to approximately 5 years, 10 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation - GEN1046 25 mg3/4 (75%)2/4 (50%)4/4 (100%)
Dose Escalation - GEN1046 50 mg5/5 (100%)2/5 (40%)5/5 (100%)
Dose Escalation - GEN1046 80 mg7/9 (77.8%)6/9 (66.7%)9/9 (100%)
Dose Escalation - GEN1046 100 mg5/6 (83.3%)3/6 (50%)5/6 (83.3%)
Dose Escalation - GEN1046 140 mg6/6 (100%)5/6 (83.3%)6/6 (100%)
Dose Escalation - GEN1046 200 mg9/9 (100%)8/9 (88.9%)9/9 (100%)
Dose Escalation - GEN1046 400 mg9/9 (100%)2/9 (22.2%)8/9 (88.9%)
Dose Escalation - GEN1046 800 mg8/9 (88.9%)4/9 (44.4%)8/9 (88.9%)
Dose Escalation - GEN1046 1200 mg2/4 (50%)2/4 (50%)4/4 (100%)
Expansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W34/40 (85%)23/40 (57.5%)39/40 (97.5%)
Expansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W16/24 (66.7%)12/24 (50%)22/24 (91.7%)
Expansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3W29/38 (76.3%)19/38 (50%)38/38 (100%)
Expansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3W2/2 (100%)0/2 (0%)2/2 (100%)
Expansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3W26/40 (65%)14/40 (35%)39/40 (97.5%)
Expansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3W7/8 (87.5%)2/8 (25%)8/8 (100%)
Expansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W23/32 (71.9%)12/32 (37.5%)31/32 (96.9%)
Expansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3W14/21 (66.7%)10/21 (47.6%)19/21 (90.5%)
Expansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3W16/19 (84.2%)7/19 (36.8%)18/19 (94.7%)
Expansion - Cervical Cancer - GEN1046 100 mg 1Q3W28/40 (70%)19/40 (47.5%)38/40 (95%)
Expansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W7/11 (63.6%)2/11 (18.2%)9/11 (81.8%)
Expansion Docetaxel Arm - GEN1046 100 mg 1Q3W + Docetaxel11/20 (55%)9/20 (45%)20/20 (100%)
Expansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6W21/27 (77.8%)10/27 (37%)27/27 (100%)
Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3W5/12 (41.7%)9/12 (75%)12/12 (100%)
Expansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6W6/10 (60%)2/10 (20%)10/10 (100%)
Expansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy Doublet8/16 (50%)7/16 (43.8%)15/16 (93.8%)
Expansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy6/8 (75%)5/8 (62.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 132
Most frequent serious events
EventDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
General physical health deteriorationGeneral disorders and administration site conditions0/40/50/92/61/61/91/91/91/45/401/241/380/20/400/81/322/210/190/400/110/200/270/120/100/160/8
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/50/91/60/63/90/91/90/42/400/240/380/21/400/81/321/210/190/400/110/200/270/120/100/160/8
Acute kidney injuryRenal and urinary disorders0/40/50/90/60/60/90/90/91/40/400/240/380/22/401/80/320/210/192/400/111/201/270/120/100/160/8
Spinal cord compressionNervous system disorders1/40/50/90/60/60/90/91/90/41/400/242/380/20/400/80/320/210/190/400/110/200/270/120/100/160/8
Intestinal obstructionGastrointestinal disorders1/40/50/90/60/60/90/91/90/40/400/242/380/21/400/80/321/210/190/400/110/200/270/120/100/160/8
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/40/50/90/60/60/90/90/90/40/400/240/380/20/400/80/320/210/190/400/110/200/270/120/100/160/8
HypernatraemiaMetabolism and nutrition disorders0/40/50/90/60/60/90/90/91/40/400/240/380/20/400/80/320/210/190/400/110/200/270/120/100/160/8
Febrile neutropeniaBlood and lymphatic system disorders1/40/51/90/60/60/90/90/90/41/400/241/380/20/400/81/321/210/190/400/112/200/270/120/102/160/8
BronchitisInfections and infestations0/40/52/90/60/60/90/90/90/40/400/240/380/20/400/80/320/210/190/400/110/200/270/120/100/160/8
Alanine aminotransferase increasedInvestigations0/40/52/90/61/61/90/90/90/41/400/241/380/21/400/81/320/210/192/400/110/200/270/120/100/161/8
Most frequent other events
Showing 10 of 484
Most frequent other events
EventDose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based Chemotherapy
Amylase increasedInvestigations0/40/50/92/62/61/91/90/90/40/401/242/382/20/400/81/320/210/191/400/111/201/273/123/101/160/8
Alanine aminotransferase increasedInvestigations1/41/52/92/61/62/91/92/93/45/405/244/380/29/403/818/321/2110/1915/401/113/202/276/123/106/164/8
Aspartate aminotransferase increasedInvestigations1/41/52/92/63/62/91/90/93/42/404/244/380/29/403/814/322/219/1914/401/112/205/276/123/106/165/8
Blood alkaline phosphatase increasedInvestigations0/40/50/90/61/60/91/90/93/40/400/241/380/21/400/83/321/210/193/400/111/203/272/120/101/162/8
FatigueGeneral disorders and administration site conditions2/42/52/92/60/61/91/90/91/48/407/245/380/214/404/86/323/212/1910/401/1115/204/275/123/105/163/8
AnaemiaBlood and lymphatic system disorders1/40/52/91/63/62/92/93/92/416/404/248/381/215/401/89/325/215/1923/402/118/206/272/121/108/166/8
DiarrhoeaGastrointestinal disorders1/40/51/91/60/60/90/93/90/42/401/243/380/25/400/84/323/210/195/400/116/203/272/124/104/165/8
NeutropeniaBlood and lymphatic system disorders0/40/52/90/61/60/91/90/90/41/403/240/380/21/400/85/321/211/193/401/110/202/270/121/1010/165/8
NauseaGastrointestinal disorders1/41/52/91/60/61/91/90/92/47/404/246/380/27/402/86/322/212/195/400/1110/207/273/126/108/162/8
AstheniaGeneral disorders and administration site conditions1/40/55/91/60/63/91/91/92/415/408/2412/380/26/400/810/324/218/1914/400/110/208/273/122/100/160/8

Baseline characteristics

The Full Analysis Set (FAS), which consisted of all participants enrolled and treated with at least 1 dose of GEN1046.

Age, Categorical
Age, Categorical(Participants)Dose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based ChemotherapyTotal
<=18 years000000000000000000000000000
Between 18 and 65 years43754558322121411972513737414103395249
>=65 years02212441118122412117812376179773180
Age, Continuous
Age, Continuous(years)Dose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based ChemotherapyTotal
Mean47.8 ± 11.665.6 ± 1155.2 ± 10.947.7 ± 20.660.5 ± 9.957.1 ± 14.462.2 ± 7.956.1 ± 13.355.5 ± 13.762.8 ± 8.565.2 ± 9.469.1 ± 9.368.5 ± 1264 ± 11.148.9 ± 11.855.1 ± 11.363.4 ± 765.3 ± 7.251.7 ± 7.967.8 ± 7.561.4 ± 7.666.4 ± 966 ± 6.669.9 ± 6.262.8 ± 8.762.3 ± 6.761.6 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based ChemotherapyTotal
Female224344531131270408323540010122581226
Male23532546327123120001814011101510587203
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based ChemotherapyTotal
Hispanic or Latino1001200001210103045000101023
Missing000000000000000000001000001
Not Hispanic or Latino3595499943922372398292115351119271110158405
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation - GEN1046 25 mgDose Escalation - GEN1046 50 mgDose Escalation - GEN1046 80 mgDose Escalation - GEN1046 100 mgDose Escalation - GEN1046 140 mgDose Escalation - GEN1046 200 mgDose Escalation - GEN1046 400 mgDose Escalation - GEN1046 800 mgDose Escalation - GEN1046 1200 mgExpansion - NSCLC (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - NSCLC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Eligible) - GEN1046 100 mg 1Q3WExpansion - Urothelial Carcinoma (Platinum Ineligible) - GEN1046 100 mg 1Q3WExpansion - Endometrial Carcinoma - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Pre-Treated) - GEN1046 100 mg 1Q3WExpansion - TNBC (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Pre-treated) - GEN1046 100 mg 1Q3WExpansion - SCCHN (PD-1/PD-L1 Naive) - GEN1046 100 mg 1Q3WExpansion - Cervical Cancer - GEN1046 100 mg 1Q3WExpansion - NSCLC Treatment Naive PD-L1 Low or High GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion Docetaxel Arm - GEN1046 100 mg 1Q3W + DocetaxelExpansion - NSCLC - GEN1046 100 mg 1Q3W + GEN1046 500 mg 1Q6WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q3W + Pembrolizumab 200 mg 1Q3WExpansion - Pembrolizumab Combination - GEN1046 100 mg 1Q6W + Pembrolizumab 400 mg 1Q6WExpansion - NSCLC Non-Squamous - GEN1046 100mg + Pembro 200mg + Platinum-based Chemotherapy DoubletExpansion - NSCLC Squamous - GEN1046 100mg 1Q3W + Pembro 200mg 1Q3W + Platinum-based ChemotherapyTotal
American Indian or Alaska Native000000000000000000000000000
Asian Indian000000000000000000000000000
Asian Other000000000100000020000100004
Black or African American0010000001100212100051011017
Chinese000000000000000000000000000
Japanese000000000000000000000000000
Malay000000000000000000000000000
Missing000000000000000000000000000
Native Hawaiian or Other Pacific Islander000000000000000000000000000
Not Reported000000000000000000000000000
Other000000000100010000000000002
White458669994372338237730181940111525129158406
08

Study locations

57 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Yale University Cancer Center
    New Haven, Connecticut 06520-8028, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Iowa Hospitals
    Iowa City, Iowa 52242, United States
  • Norton Healthcare Inc
    Louisville, Kentucky 40202, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • NYU Langone
    New York, New York 10016, United States
  • UNC Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Levine Cancer Institute, Atrium Health
    Charlotte, North Carolina 28204, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Fakultni nemocnice Brno
    Brno, Czechia
  • University Hospital Brno
    Brno, Czechia
  • Nemocnice AGEL Ostrava-Vítkovice a.s.
    Nový Jičín, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, Czechia
  • High Technology Hospital Medcenter
    Batumi, Georgia
  • LLC "TIM - Tbilisi Institute of Medicine"
    Tbilisi, Georgia
  • LTD Consilium Medulla
    Tbilisi, Georgia
  • Tbilisi State Medical University and Ingorovka High Medical Technology University Clinic Ltd
    Tbilisi, Georgia
  • Onkologiai Klinika
    Debrecen, Hungary
  • BKMK Hospital
    Kecskemét, Hungary
  • Pulmonology Hospital Törökbálinti
    Törökbálint, Hungary
  • Rambam Health Care Campus RHCC - Rambam Medical Center
    Haifa, Israel
  • Hadassah Medical Organization HMO - Sharett Institute of Oncology
    Jerusalem, 12000, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Sheba Medical Center, Ramat Gan
    Tel Litwinsky, 52621, Israel
  • Policlinico San'Orsola
    Bologna, Italy
  • IRCCS - Istituto Europeo di Oncologia IEO
    Milan, Italy
  • Istituto Nazionale Tumori - Fondazione Pascale Italy
    Naples, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, Italy
  • AUSL Romagno-Ravenna
    Ravenna, Italy
  • Policlinico Uni. Campus Bio-Medico
    Roma, Italy
  • Regina Elena National Cancer Institute
    Rome, Italy
  • ASST Sette Laghi "Ospedale di Circolo e Fondazione Macchi "
    Varese, Italy
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • Medpolonia Sp. z o.o.
    Poznan, Poland
  • Specialist Hospital in Prabuty
    Prabuty, Poland
  • Dom Lekarski SA
    Szczecin, Poland
  • Maria Sklodowska Curie National Research Instutute of Oncology
    Warsaw, Poland
  • Hospital Universitario Vall dHebron
    Barcelona, 08035, Spain
  • IOB-Hospital Quironsalud Barcelona
    Barcelona, 8023, Spain
  • START Madrid-FJD, Hospital Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • START Madrid-CIOCC
    Madrid, 28050, Spain
  • NEXT Oncology Madrid
    Madrid, 28223, Spain
  • Hospital Universitario La Princesa
    Madrid, Spain
  • MD Anderson Cancer Center Madrid
    Madrid, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Spain
  • Clinica Universidad de Navarra
    Pamplona, 31008, Spain
  • Hospital Clinico De Valencia
    Valencia, 46010, Spain
  • Gulhane Training and Research Hospital
    Ankara, Turkey (Türkiye)
  • Medical Point Izmir Hospital
    Cordaleo, Turkey (Türkiye)
  • Trakya University Hospital
    Edirne, Turkey (Türkiye)
  • ARENSIA Exploratory Medicine LLC
    Kyiv, Ukraine
09

References and documents

Publications

  • Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sanger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Tureci O, Forssmann U, Ahmadi T, Sahin U, Jure-Kunkel M, Melero I. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265. doi: 10.1158/2159-8290.CD-21-1345. PubMed 35176764 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Apr 2025, 70 months.

Results were first posted in Aug 2026, 1 year 4 months after primary completion. A results delay was requested in Jan 2026.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2019
First posted
Apr 17, 2019
StartActual
May 14, 2019
Primary completionActual
Apr 1, 2025
CompletionActual
Aug 3, 2026
Results delay requested
Jan 15, 2026
Results first posted
Aug 4, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03917381
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Apr 17, 2019
Start date
May 14, 2019
Primary completion
Apr 1, 2025
Completion
Aug 3, 2026
Results posted
Aug 4, 2026
Last update
Sep 9, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acasunlimab · Docetaxel · Pembrolizumab

Start the discussion